Navigation Links
Myriant Technologies LLC Announces Appointment of Science Advisory Board Members

QUINCY, Mass., Oct. 21 /PRNewswire/ -- Myriant Technologies LLC (Myriant), a privately-held, biotech developer and manufacturer of renewable biochemicals, announced the formation of its Science Advisory Board and the appointment of distinguished Board members. Board members individually and collectively will provide broad insight into all aspects of the technology and business of converting renewable biomass feedstocks into valuable chemicals.

(Logo: )

Collectively, the Board members have outstanding credentials as scientists in the biotechnology fields of specific interest to Myriant, including: molecular biology, genetic and metabolic pathway engineering, micro-organism development and related fermentation process development.

Myriant's Science Advisory Board members include:

  • Dr. Stephen J. Benkovic, Evan Pugh Professor and Eberly Chair in Chemistry at Penn State University, and member of the National Academy of Sciences and its Institute of Medicine;
  • Dr. Joseph Glas, Executive Vice President and Advisory Board Chairman, Myriant;
  • Dr. Lonnie Ingram, Distinguished Professor, Department of Microbiology and Cell Science, University of Florida, and Director, Florida Center for Renewable Chemicals and Fuels, and member of the National Academy of Sciences;
  • Dr. Jan Westpheling, Professor, Department of Genetics, University of Georgia; and
  • Dr. Huimin Zhao, Professor, Centennial Endowed Chair of Chemical and Biomolecular Engineering, University of Illinois.

"I am honored and we are fortunate to have such an exceptional group of scientists as advisors to Myriant," said Stephen J. Gatto, Chairman and Chief Executive Officer of Myriant. "Under the leadership of Dr. Joe Glas, I have great confidence that we will reap immediate and long term benefits from their advice and input."

"The pace of change in Myriant's field of industrial biotechnology is ever accelerating," added Dr. Glas. "Our cutting-edge research and development team will benefit enormously from the addition of this unique expertise and its impact on our paths to commercialization."

With a world-renowned team of molecular biologists, engineers and chemists, Myriant utilizes proprietary technology to advance the development of low-cost cellulosic sugars for the sustainable commercialization of high-value specialty chemicals. The company's D(-) lactic acid started production at commercial scale in June 2008 for use in polylactic acid. Myriant will begin commercial production of its second product, biobased succinic acid, in 2010. Myriant is headquartered in Quincy, Massachusetts. Further information is available at

    Contact: Samuel G. McConnell
    Sr. VP, Corporate Development

SOURCE Myriant Technologies LLC

SOURCE Myriant Technologies LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioEnergy International, LLC Announces Formation of Myriant Technologies LLC
2. China Medical Technologies to Exhibit its Products at China International Medical Equipment Fair in Chengdu, China
3. Epeius Biotechnologies to Partner at BIO Investor Forum
4. Neurobiological Technologies Announces Intent to File Form 25 to Delist Common Stock From the NASDAQ Capital Market
5. OriGene Technologies Acquires Marligen Biosciences
6. China Medical Technologies Announces the SFDA Approval for its SPR System
7. Global Med Technologies(R), Inc. Licenses EdgeLab to Seven Laboratories at University Hospital of Reims, France
8. Varian, Inc. Announces Stockholder Approval of Merger Agreement With Agilent Technologies
9. TOPAZ Technologies Protocols for Animal Studies Software Drives Customer Conversions
10. Global Med Technologies(R) Signs Binding LOI With European Company for Breakthrough Transfusion Safety RFID Product
11. Variation Biotechnologies Names Jeff Baxter CEO
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading ... the Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio ... and clinical trial team. , Using the CONSULT module, patients and physicians can schedule ...
(Date:6/27/2016)... N.C. (PRWEB) , ... June 27, 2016 , ... ... commercial operations for Amgen, will join the faculty of the University of ... as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus ...
(Date:6/27/2016)... BOSTON , June 27, 2016   Ginkgo ... biology to industrial engineering, was today awarded as ... a selection of the world,s most innovative companies. ... at scale for the real world in the ... organism engineers work directly with customers including Fortune ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
Breaking Biology Technology:
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/12/2016)... , May 12, 2016 ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):